Abstract
Recently, cell based therapy become a popular topic in research fields. This therapy offers great potential to treat many diseases. Adipose-derived stem cell (ASCs) is known to have the special characteristic due to its abundant availability and easily harvesting. Then it rapidly advanced into clinical trials for treatment of a broad range of medical conditions. Before translating ASCs from bench to bedside, this process is facing other problems through fetal bovine serum (FBS) elimination. Animal-derived serum is not a suitable option for ASCs expansion regarding the possibility of viral or bacterial infection and immune reaction. By replacing FBS with other non-animal serum which gives the same effect as FBS, may significantly enhances the safety and quality of ASCs. Pooled human AB serum (AB-HS), human serum (HS), pooled human plasma lysate (PL), umbilical cord serum (UCS)/placental serum (PS), thrombinactivated platelet rich plasma (tPRP) or serum free (SF)/xeno-free (XF) have been considered as FBS alternatives and some already applied in clinical trials with human cells. This article focuses on a prospective alternatives serum through the elimination of FBS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
